This report focuses on the global Companion Diagnostic Tests in Oncology status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Companion Diagnostic Tests in Oncology development in United States, Europe and China.
Increasing incidence of cancer, rising cost burden of cancer treatment, and increasing mortalities due to cancer, are some of the major reasons for increasing demand for new and technologically advanced treatment options, therapies, and drugs for the treatment of cancer.
In 2017, the global Companion Diagnostic Tests in Oncology market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.
The key players covered in this study
Abbott
Roche
Genomic Health
QIAGEN
Agilent
Agendia
BioMerieux
Illumina
Siemens Healthcare
Thermo Fisher
Market segment by Type, the product can be split into
Protein Detection
DNA Detection
Market segment by Application, split into
Pharmaceutical & Biotechnology Companies
Medical Device Companies
Research Institutes
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Companion Diagnostic Tests in Oncology status, future forecast, growth opportunity, key market and key players.
To present the Companion Diagnostic Tests in Oncology development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Companion Diagnostic Tests in Oncology are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.